Literature DB >> 21616640

Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage.

Noriaki Kume1, Hirokazu Mitsuoka, Kazutaka Hayashida, Masaru Tanaka.   

Abstract

BACKGROUND: Pentraxin 3 (PTX3) is increased in circulating blood during the acute stage of acute coronary syndrome (ACS). Therefore, we compared diagnostic values of PTX3 for ACS with those of biomarkers for myocardial damage, such as troponin T (TnT) and heart-type fatty acid binding protein (H-FABP). METHODS AND
RESULTS: Patients (n = 87) undergoing coronary angiography (CAG), consisting of 16 ACS and 71 non-ACS patients were enrolled. Non-ACS consists of 12 patients with normal CAG, 30 stable angina pectoris (SAP) patients controlled by medical treatment, and 29 SAP patients who required elective coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft). Age, gender, or prevalence of diabetes, hypertension, or smoking was not significantly different between ACS and non-ACS groups. Serum total, high-density lipoprotein, or low-density lipoprotein cholesterol, or triglyceride levels were not significantly different between ACS and non-ACS. PTX3 levels were not significantly correlated with lipid profiles or different between those with and without conventional risk factors. Circulating PTX3, TnT, and H-FABP levels were significantly higher in ACS than non-ACS. In receiver-operating characteristic (ROC) curves, area under the curve (AUC) values for PTX3, TnT and H-FABP were 0.920, 0.674, and 0.690, respectively. ROC curves of PTX3 (AUC: 0.901), TnT (AUC: 0.731), and H-FABP (AUC: 0.633) for ST-elevation ACS were similar to those for whole ACS. In a TnT-negative subgroup, the AUC values of PTX3 and H-FABP for ACS were 0.981 and 0.489, respectively.
CONCLUSIONS: PTX3 is a sensitive and specific biomarker for the diagnosis of ACS, and shows additional diagnostic values when measured in combination with TnT.
Copyright © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21616640     DOI: 10.1016/j.jjcc.2011.03.006

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  16 in total

1.  Pentraxin 3: A Biomarker Link between Inflammation and Cardiovascular Risk among Obese Children.

Authors:  Yan-Ting Chen; Hui-Hsuan Wang; Ping-Yen Liu
Journal:  Acta Cardiol Sin       Date:  2021-03       Impact factor: 2.672

2.  Serum H-FABP levels in patients with hypothyroidism.

Authors:  Fahri Gunes; Mehmet Asik; Ahmet Temiz; Ahmet Vural; Hacer Sen; Emine Binnetoglu; Neslihan Bozkurt; Zeliha Tekeli; Gokhan Erbag; Kubilay Ukinc; Erdem Akbal
Journal:  Wien Klin Wochenschr       Date:  2014-09-19       Impact factor: 1.704

3.  Morning pentraxin3 levels reflect obstructive sleep apnea-related acute inflammation.

Authors:  Yusuke Kobukai; Takashi Koyama; Hiroyuki Watanabe; Hiroshi Ito
Journal:  J Appl Physiol (1985)       Date:  2014-09-18

4.  The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.

Authors:  V Buda; M Andor; C Cristescu; M Voicu; F Cochera; P Tuduce; L Petrescu; M C Tomescu
Journal:  Ir J Med Sci       Date:  2017-02-21       Impact factor: 1.568

5.  PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophages.

Authors:  Tangmeng Guo; Li Ke; Benling Qi; Jingjing Wan; Jing Ge; Lijuan Bai; Bei Cheng
Journal:  J Clin Immunol       Date:  2011-12-16       Impact factor: 8.317

6.  Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury.

Authors:  Jianlin Chen; Martin M Matzuk; Xin J Zhou; Christopher Y Lu
Journal:  Kidney Int       Date:  2012-08-15       Impact factor: 10.612

7.  Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.

Authors:  Anna Witasp; Mikael Rydén; Juan Jesús Carrero; Abdul Rashid Qureshi; Louise Nordfors; Erik Näslund; Folke Hammarqvist; Samsul Arefin; Karolina Kublickiene; Peter Stenvinkel
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

8.  Evaluation of Serum Pentraxin-3 Level in Patients with Acute Myocardial Infarction Compared with Control Group.

Authors:  Alireza Firouzjahi; Saeedeh Eris; Seyed Farzad Jalali; Ali Bijani; Mohammad Ranaee
Journal:  Iran J Pathol       Date:  2021-05-09

9.  Assessment of short-term prognosis by sinus heart rate turbulence in patients with unstable angina.

Authors:  Zhen-Qiang Sheng; Ye-Fei Li; Gang Lin; Yi Wang; Hui-He Lu
Journal:  Exp Ther Med       Date:  2013-02-08       Impact factor: 2.447

10.  Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps.

Authors:  Kenji Daigo; Takao Hamakubo
Journal:  Front Immunol       Date:  2012-12-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.